Navigation Links
Nanoly Bioscience to Develop CU-Boulder Vaccine Stabilization Technology

Boulder, CO (PRWEB) September 11, 2013

Nanoly Bioscience of Boulder and the University of Colorado recently entered into an option agreement that will enable the startup company to develop a technique for protecting vaccines during delivery to rural and less-developed areas of the world.

The most needed vaccines in developing countries are for measles, tetanus, polio, pertussis and diphtheria, all of which — like most vaccines — must be kept at between 35-45 degrees Fahrenheit (2-8 degrees Centigrade) during transportation, delivery and storage. Outside of this range, vaccines begin to degrade and become ineffective. Maintaining this “cold chain” during transportation and delivery is challenging even in developed areas, and storing vaccines at appropriate temperatures is a serious problem in remote areas where electricity is absent or unreliable.

A research team led by CU-Boulder Distinguished Professor Kristi Anseth of the chemical and biological engineering department and the BioFrontiers Institute developed a unique material that is being adapted to solve the problem, which is estimated by the World Health Organization to cause more than a quarter of the total wastage of liquid vaccines worldwide. Anseth’s group created a unique “nano-polymer” material that can be customized and blended with any vaccine to protect against thermal damage during transportation, ultimately improving vaccine availability in remote locations.

“We’re thrilled to be adapting CU technology and working toward a solution for such an important problem,” said Balaji Sridhar, a member of Anseth’s lab who co-founded Nanoly in 2012 along with Anseth lab colleague Mark Tibbitt and co-founders from several other institutions. In 2013, the company placed second in the CU Denver business plan competition. Nanoly Bioscience also won the Duke University Startup Challenge in 2012.

“We are excited that Nanoly has optioned Dr. Anseth’s polymer technology,” said MaryBeth Vellequette of the University of Colorado Technology Transfer Office, who is the director of technology transfer for CU-Boulder. “Nanoly has a very dynamic team that is passionate about developing this technology and we are eager to continue working with them as this venture grows.”

The CU Technology Transfer Office pursues, protects, packages and licenses to business the intellectual property generated from research at CU. The office provides assistance to faculty, staff and students, as well as to businesses looking to license or invest in CU technology. For more information about technology transfer at CU visit

For more information about Nanoly Bioscience visit For more information about CU-Boulder visit For more information on the CU System visit


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
8. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Roka Bioscience Secures $47.5 Million in Series D Financing
11. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
Breaking Biology News(10 mins):